News | Atrial Fibrillation | August 23, 2023

New Device Helps Prevent Complication During Common Heart Procedure

By gently diverting the esophagus, heart ablations will be safer 

By gently diverting the esophagus, heart ablations will be safer

Emile Daoud, MD, helped develop a new surgical device at The Ohio State University Wexner Medical Center to prevent a common and serious complication during heart ablation procedures. The device gently moves the nearby esophagus away from the heart to prevent the ablation energy from causing damage. Image courtesy of The Ohio State University Wexner Medical Center 

 


August 23, 2023 — Atrial fibrillation, or AFib , is the most common heart rhythm problem, affecting millions of Americans and greatly increasing their risk of stroke and heart failure. For some with AFib, a catheter ablation is used to burn or freeze the precise area causing the problem to restore a normal heart rhythm. While this method is effective in treating AFib, the energy from the catheter tip can cause serious damage to the adjacent esophagus, which is only a few millimeters away. It’s an injury that can be life threatening, so an electrophysiologist at The Ohio State University Wexner Medical Center helped develop a new device that gently diverts the esophagus out of harm’s way, greatly improving safety.  

“On one hand, we want to deliver high energy and spend a lot of time ablating a specific spot to get a good, deep lesion. But on the other hand, we are very cognizant of where the esophagus is and want to do everything possible to avoid damaging that structure,” said Emile Daoud, MD, electrophysiologist and clinical professor of internal medicine at the medical center. “By pulling in the esophagus using suction force and then moving the entire segment to the side by about an inch, we are able to create a safe pathway to deliver the energy to treat AFib.” 

A clinical trial led by Ohio State found that without the device, over a third of heart ablation patients had esophageal injuries, but when the new device was used, less than 5% of patients had any injury to the esophagus, and they were much less severe than the control group. 

“There have been attempts to protect the esophagus during heart ablations in the past using different techniques like measuring the temperature inside the esophagus, using ultrasound imaging to identify where it’s located and using shorter or less intense ablation energy, but esophageal injury continued to be a serious problem,” said Daoud. “With this device, patients can rest assured that they are getting the safest procedure possible without compromising any benefits to their heart.” 

For more information: https://wexnermedical.osu.edu/ 


Related Content

News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
News | Atrial Fibrillation

December 22, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home December 22, 2023
Home
News | Atrial Fibrillation

December 14, 2023 — Medtronic plc, a global leader in healthcare technology, today announced that the United States Food ...

Home December 14, 2023
Home
Subscribe Now